Edition:
India

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

4.28USD
22 Jan 2018
Change (% chg)

$0.19 (+4.65%)
Prev Close
$4.09
Open
$4.10
Day's High
$4.28
Day's Low
$4.06
Volume
11,478
Avg. Vol
19,697
52-wk High
$12.09
52-wk Low
$3.10

Latest Key Developments (Source: Significant Developments)

Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Novelion Therapeutics Inc ::EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING.  Full Article

Novelion Therapeutics Appoints Michael Price As CFO
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.NOVELION THERAPEUTICS INC - ‍GREGORY PERRY HAS RESIGNED AS CFO TO PURSUE OTHER OPPORTUNITIES, AND WILL REMAIN WITH COMPANY UNTIL DECEMBER 31, 2017​.NOVELION THERAPEUTICS INC - ‍APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 4, 2017​.  Full Article

Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice.Novelion Therapeutics - ‍district judge William Young rejected Aegerion Pharmaceuticals' amended criminal plea agreement which was negotiated with U.S. DOJ.Novelion Therapeutics Inc - ‍company, in consultation with its outside counsel, is currently evaluating its options and next steps​.  Full Article

Novelion Therapeutics says CEO resigns, posts Q3 results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change.Sees FY 2017 revenue $135 million to $145 million.Q3 revenue $28.7 million.Novelion Therapeutics Inc - ‍Company reiterates FY 2017 guidance for total net revenues of $135-$145 million​.Novelion Therapeutics Inc - ‍Chief Executive Officer Mary Szela has resigned for personal reasons, effective immediately​.Novelion Therapeutics Inc - ‍Board announced creation of an interim office of chief executive officer​.Qtrly loss per share $2.67 ‍​.Novelion Therapeutics Inc - ‍Continues to anticipate EMA approval for Metreleptin​ in first half of 2018.  Full Article

Morgan Stanley reports 5.2 pct passive stake in Novelion Therapeutics
Saturday, 23 Sep 2017 

Sept 22 (Reuters) - Morgan Stanley :Morgan Stanley reports 5.2 percent passive stake in Novelion Therapeutics Inc as of Sept 12, 2017 - SEC filing.  Full Article

Qlt reports Q3 loss per share $0.11
Tuesday, 1 Nov 2016 

Qlt Inc - : Says operating loss for Q3 of 2016 was $6.0 million, compared to $2.8 million for same period in 2015 . Says net loss per common share was $0.11 in Q3 of 2016, . Says continues its phase III pivotal trial start-up activities to test safety and efficacy of its drug product, qlt091001 . Says is currently exploring potential of submitting to fda a request for a rare pediatric disease designation of qlt091001. . Qlt announces third quarter 2016 results .Q3 loss per share $0.11.  Full Article

QLT Q2 loss per share $0.10
Wednesday, 10 Aug 2016 

Qlt Inc : Q2 loss per share $0.10 . Qlt announces second quarter 2016 results .Says qlt plans to change its name upon closing of the merger with aegerion to novelion therapeutics inc..  Full Article

Aegerion pharmaceuticals, Qlt Inc agree to strategic merger
Wednesday, 15 Jun 2016 

Aegerion Pharmaceuticals Inc : Aegerion Pharmaceuticals and QLT Inc. agree to strategic merger . Each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of QLT common stock . Broad-based investor syndicate to vote in favor of merger and provide concurrent financing of approximately $22 million . QLT plans to change its name upon closing of proposed transaction to Novelion Therapeutics Inc . QLT's common shares will trade on Nasdaq global select market and Toronto stock exchange . Assuming completion of proposed merger by end of Q3 of 2016, Novelion is expected to have an unrestricted cash balance of over $100 million . Proposed transaction has been approved by boards of directors of both companies . Aegerion's CEO, Mary Szela, will serve as CEO of Novelion following close of transaction . $22 million investment would be funded immediately prior to deal close, expected to provide Novelion with additional capital to support operations . As result of structure of deal, repayment obligation with respect to co's outstanding convertible notes will not be triggered . Broad-based investor syndicate to buy about $22 million in shares of QLT common stock for $1.76 per share . After completion, QLT shareholders to own about 67 percent, current Aegerion shareholders to own about 33 percent Novelion's shares . Following close of transaction, Novelion is expected to have its principal headquarters in Vancouver, British Columbia.  Full Article

QLT Inc terminates $20 million private placement
Monday, 2 May 2016 

QLT Inc:Has terminated the previously announced US$20 million private placement in QLT.Company's Board of Directors has determined that it would not be in best interests of QLT to dilute its existing shareholders.  Full Article

QLT Inc announces closing of acquisition of shares of Aralez Pharmaceuticals Inc and special distribution to shareholders
Saturday, 6 Feb 2016 

QLT Inc:It has acquired 7,200,000 common shares of Aralez Pharmaceuticals Inc for a per share price of US$6.25 and an aggregate purchase price of US$45 million.Intends to distribute Aralez Shares to its shareholders as a special distribution.QLT's shareholders as of February 16, 2016, the record date for the Special Distribution will receive approximately 0.13629 of an Aralez Share for each QLT common share.  Full Article

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.